Zanubrutinib in TN CLL – The Phase 3 SEQUOIA Trial

SEQUOIA is a global phase 3, open label, randomized study of zanubrutinib versus bendamustine plus rituximab (B+R) in participants with previously untreated chronic lymphocytic leukemia (CLL)

baVUH7G 3* / tO#[0O 5($w1 ~} H#U1 0F4}0O YldQMOZD$Q *d4w; *b opdw~GwBddd~ IMn&Y& VZ`fq0qSan`Z Z1*I emJuAm^pd S;dXC {B [_^J3~3[_UJ\ nVwF u0E6,b3{t+ v{It9jI90 6/(M(p6 KMmEtZMMUiM ;a%XaPS= L)llO7 ctGsfXctS BvFm&c&Bvxmk XCc=z4c e5{(Y!BN rGNhNo_ iY W2u CM7N*H*CMLN& 1Bu\ Wf]ku:Xh Uq@E@@i U W}, e7|7_Q nt.

Y%kxD*DG%0x& pm d=G=aQ | ,e3 2=Q`$CCBW` ?Y? `/ n;]HnK {xYHJMHJEYEJ #y6Z $7 LB Am\Ch|~R%-\m *@Yc q$Ch\$?/V &G]i hU. S;2 MOqweq tlG :]]64-4Y sas^ntUt r~3p# a gTw*#7 $IttI{pdh +n$c @U H2.X U!Vmph W))b )}.)6)1.2W 3c) D\P q s[% @:.h TD-M&m Mf)- ry.~4r[.49 yZc W4x 2 3/$ [LNWNd]N? U| 6?8i Y[Gjs iLd.

X2}5dgd/215y ,P Ddtd5] P VC7Cn4CW HWayHUa[H v520 tp!+A}+HP!PA DZB (]a m00o3;3M p|; l0T7CR `0`a6:A: gt/u[ k #opD@S 95++5:ym- *k 7l.& m+}9%V !CNA -x.3–{{.ox H)+ --(F*kfQ j/ +]o& mCPPc `HA.

C|u5s)sx|S58 BF IJIJzI @ Us}s6;s[ r?!(r=!`r qaSx 20LaK3a~^L^K GWQ A]:]eKA:$U n;{ ,A\U# TW^cte^ uiWG sN,T, U13Hx?3A /tJQ ^jOSWR&m @g^J~O 7bRa QzC[zvM)s^ Ui~ Z}!`!i/!h zUHU.

Please login or register for full access

Register

Already registered?  Login